Vaccines

PUBLISHER: 360iResearch | PRODUCT CODE: 2166744

PUBLISHER: 360iResearch | PRODUCT CODE: 2166744

Respiratory Syncytial Virus Vaccine for the Elderly Market - Global Forecast 2026-2032

PUBLISHED: October 29, 2026

PAGES: 188 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

The Respiratory Syncytial Virus Vaccine for the Elderly Market is projected to grow by USD 2.67 billion at a CAGR of 5.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.86 billion
Estimated Year [2026]	USD 1.96 billion
Forecast Year [2032]	USD 2.67 billion
CAGR (%)	5.33%

RSV Vaccination for Older Adults: Executive Overview

Respiratory syncytial virus (RSV) can cause severe lower-respiratory illness in older adults, particularly those with chronic heart or lung disease, weakened immunity, frailty, or residence in congregate settings. The introduction of vaccines for older populations has added an important prevention option alongside clinical surveillance, infection-control measures, and timely diagnosis. Policy and clinical priorities differ by age threshold, risk profile, seasonality, product authorization, and national immunization guidance.

How RSV Prevention Is Reshaping Older-Adult Care

The RSV prevention landscape is shifting from primarily supportive treatment toward risk-based prevention across primary care, pharmacy, hospitals, and long-term-care systems. Key changes include greater use of shared clinical decision-making, integration with influenza and COVID-19 vaccination workflows, stronger attention to coadministration evidence, and improved identification of high-risk older adults. Implementation also depends on product safety monitoring, seasonal timing, reimbursement, provider awareness, and public confidence.

Artificial Intelligence Strengthens RSV Immunization Operations

Artificial intelligence can support RSV prevention by identifying eligible patients from electronic health records, flagging chronic conditions associated with severe disease, predicting missed vaccination opportunities, and optimizing outreach before seasonal transmission increases. It may also improve pharmacovigilance, demand planning, appointment scheduling, and analysis of respiratory-virus surveillance. These applications require validated datasets, transparent clinical oversight, privacy safeguards, bias monitoring, and clear separation between decision support and autonomous medical decisions.

Regional Differences Shape Access and Delivery

In North America, established adult immunization infrastructure and pharmacy delivery can support uptake, while fragmented coverage rules and unequal access remain practical barriers. Europe combines strong public-health surveillance with varied national recommendations, procurement models, and reimbursement pathways. Asia-Pacific spans mature vaccination systems and settings where adult immunization infrastructure is still developing, making workforce capacity and cold-chain reliability important. Latin America faces differences in financing, primary-care reach, and seasonal patterns. The Middle East is characterized by diverse health-system capacity, substantial expatriate populations, and the need for coordinated seasonal planning. Africa requires particular attention to surveillance, risk-based prioritization, primary-care integration, and reliable supply and distribution systems.

Multilateral Groups Influence Standards and Implementation

ASEAN members may benefit from coordinated surveillance, procurement dialogue, and approaches suited to varied health-system capacity. BRICS countries represent diverse epidemiological, manufacturing, regulatory, and financing conditions, making alignment difficult but potentially valuable for evidence exchange. The European Union benefits from cross-border regulatory and public-health coordination, although national recommendations and funding decisions remain important. G7 systems generally have stronger adult immunization infrastructure and data capacity, while still facing hesitancy and delivery gaps. GCC countries can leverage concentrated healthcare networks and coordinated procurement, with attention to migrant and older-adult populations. NATO members may apply established preparedness and logistics capabilities to protect vulnerable populations, while vaccination policy remains a national responsibility.

Country Context Determines RSV Vaccine Uptake

Australia has strong immunization governance but must address geographic access and seasonal planning. Brazil and Mexico need approaches that connect public-health programs with primary care and equitable access. Canada and the United States have broad adult-vaccination delivery channels, yet coverage can vary by jurisdiction, insurance, and provider recommendation. China and India face large, diverse older populations and substantial differences between urban and rural delivery capacity. Japan and South Korea have advanced healthcare systems with opportunities for coordinated geriatric and respiratory care. France, Germany, Italy, Spain, and the United Kingdom combine established health services with differing eligibility guidance, reimbursement, and primary-care workflows. Russia's implementation context is shaped by its regulatory, procurement, surveillance, and regional healthcare structures.

Practical Priorities for Industry and Health-System Leaders

Leaders should align clinical evidence with clearly defined older-adult risk groups and communicate benefits, limitations, and safety information in plain language. Build vaccination pathways into routine primary care, pharmacies, discharge planning, and long-term-care services; coordinate RSV delivery with other seasonal immunizations where guidance permits; and use reminders targeted to clinically eligible patients. Strengthen post-authorization safety monitoring, transparent reporting, provider education, and equity audits. Partnerships with public-health agencies should focus on surveillance, cold-chain resilience, reimbursement clarity, and measurable outcomes such as recommendation rates, completed vaccinations, and severe RSV admissions avoided.

Evidence-Based Methodology for the Executive Summary

This summary uses the supplied market scope-RSV vaccination for elderly populations-and synthesizes established public-health, clinical, regulatory, and health-system considerations without presenting market estimates, shares, sizing, or forecasts. Interpretation is organized across six required regions, six multinational groups, and the specified countries. Conclusions emphasize generalizable implementation factors, including disease burden risk, eligibility policy, access, delivery infrastructure, surveillance, safety monitoring, and responsible use of artificial intelligence. Country and group observations are intentionally framed as contextual insights rather than claims of uniform national policy.

Prevention Success Depends on Trusted, Equitable Delivery

RSV vaccination can complement broader respiratory-virus prevention for older adults, but its public-health value depends on reaching people most likely to experience severe disease at the appropriate time. Effective implementation requires evidence-aligned recommendations, accessible delivery points, informed healthcare professionals, reliable safety monitoring, and sustained public confidence. Across regions and country groups, leaders should treat vaccination as part of an integrated older-adult respiratory-care strategy rather than as a standalone intervention.

Product Code: MRR-1F6B55428644

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Vaccine Type

7.1. Introduction
7.2. Live Attenuated
7.3. mRNA
7.4. Recombinant
7.5. Subunit

8. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Route Of Administration

8.1. Introduction
8.2. Intramuscular
8.3. Intranasal

9. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Age Cohort

9.1. Introduction
9.2. 65-74 Years
9.3. 75-84 Years
9.4. 85 Years And Above

10. Respiratory Syncytial Virus Vaccine for the Elderly Market, by End User

10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.4. Hospitals

11. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Distribution Channel

11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy

12. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Region

12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa

13. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Group

13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO

14. Respiratory Syncytial Virus Vaccine for the Elderly Market, by Country

14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
- 15.2.1. Concentration Ratio (CR)
- 15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. AstraZeneca plc
16.2. Bavarian Nordic A/S
16.3. BioNTech SE
16.4. Clover Biopharmaceuticals, Ltd.
16.5. CureVac N.V.
16.6. GlaxoSmithKline plc
16.7. Johnson & Johnson
16.8. Moderna, Inc.
16.9. Novavax, Inc.
16.10. Pfizer Inc.
16.11. Takeda Pharmaceutical Company Limited

17. Key Experts